Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GD2CART for H3K27M-mutant Diffuse Midline Glioma
NCT04196413Phase 1Recruiting
- Sponsor
- Stanford University
- Start
- Jun 2020
- Primary completion
- Jul 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of GD2.CAR-TVS-CTL in diffuse midline glioma (DMG) (4 arms), sponsored by Stanford University. Primary endpoints: Rate of successful manufacture of GD2CART at 14 days and Safety of the dose, route and schedule of GD2CART at 28 days. Started Jun 2020; status: recruiting.
02
Drugs
GD2.CAR-TVS-CTL
03
Conditions
diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT04196413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04196413.